Kliniken Maria Hilf GmbH Moenchengladbach — Clinical Trial Site

41 Registered trials

17 Currently recruiting

Organisation

Kliniken Maria Hilf GmbH Moenchengladbach

Location

Moenchengladbach, Germany

Identifier

ORG-100021396

Address

Viersener Strasse 450, Windberg, 41063, Germany

Departments

-
Department of Pneumology
Hämatologie, Onkologie und Gastroenterologie
Hematology, Oncology, Gastroenterology
Hematology, Oncology, Gastroenterology Department
Innere Medizin
Innere Medizin I Hämatologie/Onkologie
Innere Medizin II, Klinik fuer Kardiologie
Innere Medizin, Hämatologie und Internistische Onkologie, Gastroenterologie, Palliativmedizin
Klinik f. Kardiologie/Intern. Intensivmedizin Studienzentrum
Klinik für Hämatologie, Onkologie und Gastroenterologie
Klinik für Kardiologie
Klinik für Kardiologie, Elektrophysiologie und Intensivmedizin
Klinik für Strahlentherapie
Klinik für Strahlentherapie und Radiologische Onkologie
Kliniken Maria Hilf GmbH Moenchengladbach
Kliniken Maria Hilf GmBH, Klinik für Hämatologie, Onkologie und Gastroenterologie
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
Medizinische Klinik I
Medizinische Klinik I (Klinik f. Hämatologie, Onkologie, Gastroentereologie)
NA
Strahlentherapie
Strahlentherapie und Radioonkologie

Clinical trials at this site (41)

Search interface

Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC Pending

2024-517937-41-00 extensive stage small cell lung cancer (SCLC) 4
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Recruiting

2024-515162-13-00 Eosinophilic Asthma 5 2025-04-29
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting

2022-501697-19-01 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5 2024-06-18
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC Recruiting

2023-510506-41-00 Locally advanced, unresectable non-small-cell lung canc 4 2024-04-15
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting

2023-509278-41-00 Early Stage Follicular LymphOma 5 2022-07-04
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 4 2021-05-31